FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of FDA Warning: Hidden Dangers of Smuggled Tirzepatide FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions This is one of the biggest peptide regulatory updates in years, and it's just the beginning. The FDA has officially initiated the first step to reverse its 2023 stance, removing 12 peptides